Boston Scientific Corporation (BSX) Stock Price Today
Aura AI Summary
Key Stats
- $64.33BMarket Cap
- 12,408,372Volume
- HealthSector
- $104.9852W High
- $41.5852W Low
- 80 DaysTypical Hold Time
- $76.42BEnterprise Value
- -Div Yield
- 86% Sell | 14% BuyTrading Activity
Track Boston Scientific Corporation (BSX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Boston Scientific Corporation has traded between a low of $41.58 and a high of $104.98, highlighting its annual price range. Buy and sell Boston Scientific Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Most Recent News
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

Stocks tumble as Iambic Therapeutics and TCGX Acquisition lead losses amid IPO and merger news.
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.